MTVA

MetaVia Inc. Common Stock
MTVA
Market cap $13.8M

1.60 USD

-0.16

9.09%

At close Dec 20, 4:00 PM EST

After hours

1.62

+0.02

1.25%

1 day

-9.09%

5 days

-30.43%

1 month

-37.25%

3 months

-37.25%

6 months

-37.25%

Year to date

-37.25%

1 year

-37.25%

5 years

-37.25%

10 years

-37.25%

About: MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Employees: 8

Healthcare Pharmaceutical Preparations

–

Funds holding %

of 6,809 funds

–

Analysts bullish %